AU2001241729A1 - Protected forms of pharmacologically active agents and uses therefor - Google Patents

Protected forms of pharmacologically active agents and uses therefor

Info

Publication number
AU2001241729A1
AU2001241729A1 AU2001241729A AU4172901A AU2001241729A1 AU 2001241729 A1 AU2001241729 A1 AU 2001241729A1 AU 2001241729 A AU2001241729 A AU 2001241729A AU 4172901 A AU4172901 A AU 4172901A AU 2001241729 A1 AU2001241729 A1 AU 2001241729A1
Authority
AU
Australia
Prior art keywords
active agents
pharmacologically active
protected forms
uses therefor
therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001241729A
Inventor
Ching-San Lai
Vassil P. Vassilev
Tingmin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medinox Inc
Original Assignee
Medinox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinox Inc filed Critical Medinox Inc
Publication of AU2001241729A1 publication Critical patent/AU2001241729A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
AU2001241729A 2000-02-25 2001-02-23 Protected forms of pharmacologically active agents and uses therefor Abandoned AU2001241729A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09515043 2000-02-25
US09/515,043 US6710086B1 (en) 2000-02-25 2000-02-25 Protected forms of pharmacologically active agents and uses therefor
PCT/US2001/005977 WO2001062085A1 (en) 2000-02-25 2001-02-23 Protected forms of pharmacologically active agents and uses therefor

Publications (1)

Publication Number Publication Date
AU2001241729A1 true AU2001241729A1 (en) 2001-09-03

Family

ID=24049747

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001241729A Abandoned AU2001241729A1 (en) 2000-02-25 2001-02-23 Protected forms of pharmacologically active agents and uses therefor

Country Status (3)

Country Link
US (1) US6710086B1 (en)
AU (1) AU2001241729A1 (en)
WO (1) WO2001062085A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
AU2002305099A1 (en) 2001-03-23 2002-10-08 Protarga, Inc. Fatty alcohol drug conjugates
US8552054B2 (en) 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
US20040235801A1 (en) * 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
US8071321B2 (en) * 2002-08-29 2011-12-06 Cytocure Llc Methods for up-regulating antigen expression in tumors
AT500404A1 (en) * 2003-07-17 2005-12-15 Jsw Res Forschungslabor Gmbh CHEMICAL COMPOUNDS CONTAINED TOCOPHEROL AND AT LEAST ONE MORE PHARMACEUTICAL ACTIVE
AP2006003650A0 (en) * 2003-12-12 2006-06-30 Penwest Pharmaceuticals Co Sustained release torsemide dosage forms
PE20060272A1 (en) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2R, 3R, 4S, 5R, 2'R, 3'R, 4'S, 5'S) -2.2 '- {TRANS-1,4-CYCLOHEXANODIYLBIS- [IMINO (2 - {[2- (1-METHYL- 1H-IMIDAZOL-4-IL) ETHYL] AMINO} -9H-PURIN-6,9-DIYL)]} BIS [5- (2-ETHYL-2H-TETRAZOLE-5-IL) TETRAHYDRO-3,4-FURANODIOL] AS AN A2A AGONIST
EP1645288A1 (en) * 2004-10-07 2006-04-12 CTG Pharma S.r.l. New nuclear transcription factors regulators
US7741359B2 (en) 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US20070196482A1 (en) * 2005-12-16 2007-08-23 Penwest Pharmaceuticals Co. Sustained release torsemide dosage forms
NZ570693A (en) * 2006-03-20 2011-02-25 Pfizer Ltd Amine derivatives
WO2007129178A2 (en) * 2006-04-28 2007-11-15 Wockhardt Ltd Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic- analgesic drug and proton pump inhibitor
US20100221336A1 (en) * 2007-02-14 2010-09-02 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
US20100221334A1 (en) * 2007-07-19 2010-09-02 Fink Mitchell P Compositions including leukotriene antagonists and nsaids and methods of using the same
EP2285419A4 (en) 2008-05-20 2012-05-02 Neurogesx Inc Hepatoprotectant acetaminophen mutual prodrugs
US10987365B2 (en) * 2012-10-01 2021-04-27 Gm Pharmaceuticals, Inc. Compositions and methods for the treatment of pain
US9937262B2 (en) 2013-04-30 2018-04-10 Claus Selch Larsen Prodrugs of naproxen and diclofenac
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2147721T3 (en) * 1990-04-18 2000-10-01 Procter & Gamble Pharma QUINOLONYL ANTIMICROBIAL LACTAMS.
US5380747A (en) 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5783596A (en) 1992-10-30 1998-07-21 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor

Also Published As

Publication number Publication date
WO2001062085A1 (en) 2001-08-30
US6710086B1 (en) 2004-03-23

Similar Documents

Publication Publication Date Title
AU2001241729A1 (en) Protected forms of pharmacologically active agents and uses therefor
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
AU2466099A (en) Pharmaceutically active compounds and methods of use thereof
AU2002243277A1 (en) Methods and compositions for encapsulating active agents
AU2001236457A1 (en) Compounds and compositions for delivering active agents
PL361687A1 (en) Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein junkinases
EP1171117A4 (en) Long term administration of pharmacologically active agents
AU2002235140A1 (en) Fluidic self-assembly of active antenna
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2001284985A1 (en) Compounds and compositions for delivering active agents
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
EP1115396A4 (en) Pharmaceutically active compounds and methods of use thereof
AU2001288277A1 (en) Compounds and compositions for delivering active agents
AU2003228658A1 (en) Conjugates of membrane translocating agents and pharmaceutically active agents
AU2001272383A1 (en) Fungicidal combinations of active agents
EP1154997A4 (en) Pharmaceutically active compounds and methods of use thereof
AU1969800A (en) Combination of active agents
AU2001275036A1 (en) Protected forms of a combination of pharmacologically active agents and uses therefor
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2002316200A1 (en) Compound and composition for delivering active agents
AU2002338302A1 (en) Bioregulatory combination of active agents
HUP0303178A3 (en) Methods and compositions for reducing the taste of pharmaceutically active agents
AU2662799A (en) Modified pharmacologically active agents and improved therapeutic methods employing same
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU4980400A (en) Compositions and methods for detection of active proteases